当前位置：首页 > 文献互助 > 互助详情

Benzgalantamine (Zunveyl) for the Treatment of Mild to Moderate Alzheimer Disease复制

用户bEcv-rzIERoU 1个月前 72 10 已关闭

DOI:复制

文献链接:复制

其他信息:

EM Johnston, JL Lounsbery
American family physician, 2025
aafp.org
Benzgalantamine should improve cognitive and behavioral symptoms in patients with mild to moderate Alzheimer disease over the short-term, similarly to galantamine. Given the frequent intolerance of galantamine, benzgalantamine can be considered if intolerance occurs.

上一篇：Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol,

下一篇：GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain after nerve injury

互助时间线

2025-10-14 14:44:56 [关闭求助]

系统关闭了求助

2025-10-09 14:44:56 [发起求助]

最新发布的求助

Structure-guided design of a synthetic bile acid that inhibits Clostridioides difficile TcdB toxin 16分钟前
A focused report on IFN-1 targeted therapies for lupus erythematosus 56分钟前
Solid catalyst component for polymerization of olefins and catalyst 3小时前
Design and Analysis of Phase I Clinical Trials 3小时前
Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor 3小时前
Sudden Loss of Consciousness Following Psilocybin Ingestion 3小时前
Current updates in the epidemiology and comorbidities of atopic dermatitis 4小时前
Designer catalytic nanopores meet PET nanoparticles 5小时前
Interpretable machine learning for knowledge generation in heterogeneous catalysis 5小时前
Recent Progress in Electro- and Photocatalyst Discovery with Machine Learning 5小时前
Machine Learning for Electrocatalyst and Photocatalyst Design and Discovery 5小时前
Boron Delta-Doping in Si : B Stacks By RP-CVD Epitaxy 5小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com